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Abstract: Japanese encephalitis (ICD 10: A83.0) is an important specific viral encephalitis 
caused by the Japanese encephalitis virus, a virus of the Flavivirus group. Millions of people, 
especially those in endemic areas of developing countries in Asia, are at high risk from this 
infection. Therefore proper management to deal with this virus is essential. There is no specific 
treatment for Japanese encephalitis virus. Supportive and symptomatic treatments are usually 
used, which emphasize the importance of prevention in this specific neurological disorder. 
Vector control or vaccination can be used to prevent the disease. Because the existing Japanese 
encephalitis vaccine poses some undesirable problems, a new vaccine is needed. The process 
of developing a new vaccine is briefly discussed.
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Introduction to Japanese encephalitis1–4
Acute inflammation of the brain is the hallmark of encephalitis. Encephalitis has several 
causes, including biological, chemical and physical insults. Infection is an interesting 
cause of encephalitis. Several infections can lead to encephalitis, among which 
viral infections are important.5,6 Viral encephalitis can be fatal, and usually presents 
problems for the physician.5,6 Many viruses causing encephalitis are documented in the 
medical literature, among which Japanese encephalitis (ICD 10: A83.0) is important. 
Japanese encephalitis is a specific neurological disturbance that is caused by Japanese 
encephalitis virus, which is a member of in the Flavivirus group.7
Japanese encephalitis is classified as an important mosquito-borne infection.8–12 
Mosquito vectors are Culex spp, especially C. gelidus and C. tritaeniorhynchus.13–15 
These vectors usually live in fields and water reservoirs in rural and suburban 
areas.8–12 The disease can be frequently seen in developing countries in Asia, where 
suitable breeding sites of the mosquito vectors are abundant. Because of the nature 
of this vector-borne disease, it remains a focus of public health around the world, 
especially in tropical regions (Table 1). Because millions of people, especially those 
in developing countries, are at high risk from this viral infection, proper management 
of this disease is essential.
Another interesting feature of the transmission cycle of Japanese encephalitis 
virus is that pigs can harbor the virus and act as an amplifying host.27–31 Because the 
virus can then be further transmitted by mosquitoes to humans, it can be classified 
as a pig-related disease. The disease is common in many pig-farming areas. A case 
presenting classical viral encephalitis symptoms with a history of living in a International Journal of General Medicine 2009:2 196
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pig-farming area or having traveled to or through such 
an area should raise strong suspicions of infection with 
Japanese encephalitis.31 During disease surveillance, patients 
should be asked about their history of contact with pigs 
(pig farming, slaughtering, butchering and transport, and 
living in a pig-farming area). However, because other hosts, 
including other mammals and birds, notably water fowl, can 
amplify the disease, these should also be taken into account 
during disease surveillance and control. It should be noted 
that only 1 in 1000 patients who contract the virus from a 
mosquito bite develop a full-blown illness. However, the 
mortality from full-blown disease is very high (up to 10% 
to 20%), and two-thirds of the survivors suffer permanent 
neurological defects.
The incubation period after infection from a mosquito 
bite is usually 2 to 4 days. The common, but not specific, 
presentation is fever, either high or low. Some cases can also 
present flu-like symptoms. Most recover from the illness 
without treatment, but sometimes encephalitis develops. 
Neurological manifestations are usually the starting point 
for clinical diagnosis. Indeed, in tropical endemic areas, 
any patient presenting with fever and the neurological 
signs and symptoms should receive a complete assess-
ment for possible viral encephalitis. Briefly, the common 
symptoms include alteration of consciousness and seizure. 
An alteration in EEG is also detectable. Encephalitis is the 
presumptive diagnosis for such cases. However, because 
the neurological manifestations of Japanese encepha-
litis are highly similar to those of other kinds of viral 
encephalitis, simple clinical observation does not easily 
differentiate between Japanese encephalitis and the other 
kinds of encephalitis. A laboratory investigation is invari-
ably necessary.
As already mentioned, diagnosing Japanese encephalitis 
is not easy. The clinical diagnosis requires further verifica-
tion by standard medical laboratory investigation. Immuno-
diagnosis, the basic diagnostic laboratory test, remains the 
gold standard. However, confirmed diagnosis is usually late 
in the course of the disease because the patient will usually 
have full-blown neurological signs and symptoms before 
the physician in charge becomes aware of the possibility of 
a diagnosis of Japanese encephalitis.1–4 A few commercial 
Table 1 Situation of Japanese encephalitis in different regions of the world
Areas Details
Asia16–19  Tropical Asia is the endemic area of Japanese encephalitis.   There are many outbreaks in Asia in each year.  South Asia (especially India) 
and Southeast   Asia are the two main regions where Japanese encephalitis is prevalent. Poverty is a big underlying risk factor for 
Japanese encephalitis in Asia. However, this does not mean that there is no problem for rich countries. Of interest, Japan, from where 
the name Japanese encephalitis is derived, still has this disease although it is controlled.19
Africa Although the socioeconomic status is lower than in Asia, the prevalence of disease is nil, because of the geographical pattern 
of Japanese encephalitis. However, there is confirmed evidence for an intermediate risk of Japanese encephalitis transmission 
in Africa (compared to high risk for dengue).20
Australia Japanese encephalitis is a new emerging arbovirus infection in Australia.21–26
South America The Americas are currently not at risk of Japanese encephalitis.
Table 2 Neurological manifestations of Japanese encephalitis1–4,32–35
Aspects Descriptions
Signs and symptoms Fever (high or low), nausea and vomiting, stupor, alteration of consciousness, loss of consciousness, seizure (generalized or 
focal).
Laboratory findings Cerebrospinal fluid (CSF) profile shows white blood cells about 5–500/mm3 with lymphocyte predominance (however, 
neutrophilia can be seen in the first 3 days). CSF protein is about 50–200 mg/dL and CSF sugar is not depleted. It should be 
noted that this is not specific for Japanese encephalitis but a common CSF profile for all viral encephalitis.
Definite diagnosis Definite diagnosis is based on immunodiagnosis.1–4 Specific Japanese encephalitis IgM (by ELISA) in CSF or serum 40 units 
(in serum, the ratio of Japanese encephalitis/dengue IgM by ELISA must be more than 1). In case of death, definite diagnosis 
can also be made during autopsy. The main finding is the detection of Japanese encephalitis antigen in the brain tissue.35
eeG Alteration of eeG pattern can be seen corresponding to the presentation of seizure.   According to Misra and Kalita, “Upon 
comparison of the Je patients with and without seizures, eeG slowing and cortical and thalamic lesion on CT or MrI were 
significantly related to the occurrence of the seizures; however, it was not associated with poor outcome.”32
Imaging  There is no specific significant finding on CT or MRI.33 However, as noted by Misra and Kalita, the specific lesion that might 
be related to the seizure, but not the prognosis, should be kept in mind.32,34International Journal of General Medicine 2009:2 197
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kits for detecting Japanese encephalitis are available. 
In addition, as a vector-borne disease of poor, developing 
countries, pharmaceutical companies in the developed 
world have little interest in the disease.
As member of the Flavivirus group, there is no specific 
treatment.1–4 All cases need supportive and symptomatic 
treatment in hospital, which emphasizes the importance 
of prevention. Intravenous fluid (usually 5% dextrose half 
strength saline solution) administration at maintenance 
dose is recommended. Seizures can be treated with an 
anticonvulsive drug such as phenytoin and phenobarbital.
Vaccination36–38
Prevention can be by either vector control or vaccination. 
Mosquito control is difficult because of their sheer numbers. 
Preventing mosquito bites will be more effective than 
mosquito control, but this is also sometimes very difficult. 
Vaccination seems to be the most effective alternative 
preventive. Japanese encephalitis vaccine is available and 
used in many countries. In clinical practice, the inactivated 
mouse brain Japanese encephalitis vaccine (BIKEN/JEVAX 
vaccine) is widely used. Other vaccines are also used in 
some parts of the world, including the dead Nakayama 
strain vaccine used in parts of China and the live SA14-14-2 
vaccine used in China and some Asian countries, including 
Thailand.38,39
A three-dosage vaccination schedule is recommended to 
achieve full immunity in endemic areas in which the virus is 
endemic. It has been proved that 80% immunogenicity can 
be achieved after the second vaccination and the generated 
immunity can last for 1 year. If the third vaccination is 
completed, immunogenicity can reach 100% and the 
Table 3 Details of classical inactivated mouse brain Japanese encephalitis vaccine36–38
Aspects Descriptions
Type This is an inactivated vaccine, derived from controlled infected mouse brain.   The inactivation of the virus from infected 
mouse brain is due to formalin application.40,41 After inactivation, the vaccine is further purified.   Two main strains are used 
for production of Japanese encephalitis vaccine: Nakayama and Beijing (the latter strain is the better)
Composition 1 mL of vaccine consists of 801 µL of effective protein (97% is the antigenic protein of Japanese encephalitis virus), 
thimerosol (as preservation) and gelatin (as stabilizer)
Package There are two package forms of Japanese encephalitis vaccine including liquid and lyophilized forms: liquid form as either 
1 mL/dose (for Nakayama strain) or 0.5 mL/dose (for Beijing strain); lyophilized (freeze-dried form) as 0.5 mL/dose  
(for Beijing strain).   The lyophilized form has a longer shelf life
Administration Subcutaneous injection is recommended. For general cases, 1 dose must be injected at the deltoid area. For children aged 
less than 3 years old, half dosage is recommended for injection at the thigh area
Schedule According to the general expanded program for immunization (ePI), vaccination is suggested for children in endemic areas 
starting at 12 months.   The vaccination schedule is on day 0, 1 month and 1 year. For highly endemic areas, a fourth booster 
dosage is recommended at 5 years. For visitors to endemic areas, pre-exposure vaccination is recommended, at day 0, day 7 
and 1 month. A special extra short schedule at day 0, day 7 and day 14 is also acceptable (but offers less protection)
Contraindication36–38 The main contraindications include fever and pregnancy.   The relative contraindications are severe heart disease, severe liver 
disease, severe kidney disease and those with history of vaccine allergy or seizure within previous year
Adverse effect36–38 Localized inflammation at injection site can be seen at a rate of about 10%–20% and is most common at first dose. 
Sometimes, fever can be seen owing to the inflammation.   Angioedema can also be seen at day 1 to day 3, at about  
0.2%–0.6%, and is commonly detected at the second dose. rarely, neurological complications such as encephalopathy  
can also be detected.   Anaphylaxis due to vaccination is rare
Storage The vaccine has to be refrigerated at 2–8°C.   The diluted lyophilized vaccine can be kept for 1 day.   The shelf life for liquid 
vaccine is 1 year and the shelf life of lyophilized vaccine is about 3–5 years
Table 4 Some important problems of presently used Japanese encephalitis vaccine
Problems Causes Possible correction
1.    Induction of unwanted adverse 
neurological reactions
the nature of mouse brain-derived vaccine cell culture-based or recombinant 
vaccine by advanced biotechnology
2.    Loss of follow-up for the third 
vaccination
long interval in the present vaccination 
schedule
new single-dose vaccination
3.  expensive few manufacturers, nature of the disease, 
which is common in poor countries
promotion of equity in drug and 
vaccine tradeInternational Journal of General Medicine 2009:2 198
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generated immunity can last for at least 5 years.42–48 However, 
the risk of excessive repeated booster vaccinations has been 
noted in the medical literature.
Problems with the current vaccine
The presently used vaccine is derived from mouse brain 
and can induce unwanted adverse neurological effects. 
This is the main reason for the need to find a new vaccine. 
A vaccine based on cell culture or recombinant technology 
has the potentioal to reduce unwanted adverse neurological 
effects.49,50
Problems with vaccination
The presently used vaccination schedule, a three-dosage 
regimen over a year-long period, poses the problem of loss 
of follow-up, especially for the third dosage, resulting in 
an unsuccessful vaccination program. A single-dosage 
vaccine would overcome this disadvantage, and is the target 
of new vaccine development. Recently, a new Japanese 
encephalitis vaccine has been produced. The Japanese 
encephalitis vaccine IC-51, known as IXIARO, is the newest 
inactivated virus (strain SA(14)-14-2), which is manufactured 
in cultured Vero cells and needs only two doses in a vacci-
nation program,51,52 thus solving the problem of a too-long 
vaccination program.
Problems with vaccines
In certain situations, some specific vaccines cannot be used, 
for example, in the pregnant. This presents a challenge for 
vaccinologists.
Affordability in developing countries can limit the 
effectiveness of vaccines. Although Japanese encephalitis 
vaccination is included in the national policy of some 
countries, high cost can still be a barrier. Japanese encephali-
tis is a disease of the poor and has received very little attention 
in wealthy countries except Japan.
Finding a new vaccine 
for Japanese encephalitis
Because of the problems discussed above, a new vaccine 
for Japanese encephalitis is needed.53–55 A new vaccine 
must be more effective, safer and of higher immunogenic-
ity, and without the problems of the presently used vaccine, 
ie, adverse neurological effects and a long vaccination 
schedule.
Finding a new epitope is usually the first step in finding 
a new vaccine. The focus can be the immunogenic protein 
already used in vaccine production. Despite the protein’s 
availability, it is still difficult to find a new epitope. It is a 
time-consuming process if based on classical techniques. 
Immunomics,56–59 a new branch of bioinformatics, can be 
useful for this purpose. Since Japanese encephalitis is a viral 
infection, the favorable epitope should be a specific T cell 
epitope which has an important role in immunogenicity via 
the T cell immune system. Alternative T cell epitopes can be 
useful in developing a multi-epitope vaccine.
Once the desired epitopes have been found, a new vaccine 
can be developed. Basically, because the vaccine is usually a 
peptide, advanced protein technology can be helpful in vaccine 
production. The new Japanese encephalitis vaccine should be 
a cell culture-based vaccine or a recombinant protein-based 
vaccine. The use of current genetic recombination technology 
can help produce the desired peptide in large amounts in a 
short time. This process also guarantees the purity of the 
new peptide, which would eliminate the problem of adverse 
neurological effects with classical Japanese encephalitis 
vaccine.
The next step in the process is testing the new vaccine’s 
properties. Although they can be predicted from the vaccine’s 
expression of visible action or function through in silico 
gene expression technology, classical in vitro and in vivo 
testing are still needed to confirm the vaccine’s efficacy and 
safety.60–65 Several new new peptides have been discovered 
within the past few years, based on cell culture, recombinant 
technology or DNA technology, and their effectiveness is 
being trialed.60–65
The newest vaccine, IXIARO, was also developed by 
a cell culture technique. Its safety and efficacy have been 
confirmed, it is newly licensed in both Europe and the US, 
and is now poised to be licensed in many Asian countries.51,52 
Combined vaccines containing a specific vaccine for other 
viruses are also the focus of current developmental research 
on Japanese encephalitis vaccine.66,67 ChimeriVax-JE, a 
chimeric live attenuated vaccine using yellow fever (YF) 17D 
vaccine as a vector, is the best example.68,69 ChimeriVax-JE 
is accepted as a cost-effective prophylactic vaccine for 
Japanese encephalitis and can provide protective levels of 
neutralizing antibody after a single dose.70 ChimeriVax-JE 
can also protect against other viruses belonging to the 
Japanese encephalitis virus serocomplex.71 ChimeriVax-JE 
vaccine is licensed in some countries, for example, Thailand, 
China and India.
If the results from classical trials on a new vaccine are 
favorable, it will be launched on the market after passing the 
regulatory and registration processes of each country. Finally, 
post-marketing surveillance, similar to that for any new drug International Journal of General Medicine 2009:2 199
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or vaccine, will still be required to complete the process of 
finding a new vaccine for Japanese encephalitis.
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